Aimee Wilkin to Viral Load
This is a "connection" page, showing publications Aimee Wilkin has written about Viral Load.
Connection Strength
0.596
-
Wilkin A, Pozniak AL, Morales-Ramirez J, Lupo SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses. 2012 May; 28(5):437-46.
Score: 0.388
-
Townsend D, Troya J, Maida I, Pérez-Saleme L, Satta G, Wilkin A, Barreiro P, Pegram PS, Soriano V, Mura MS, Núñez M. First HAART in HIV-infected patients with high viral load: value of HIV RNA levels at 12 weeks to predict virologic outcome. J Int Assoc Physicians AIDS Care (Chic). 2009 Sep-Oct; 8(5):314-7.
Score: 0.084
-
Donovan J, Sullivan K, Wilkin A, Fadul N, Heine A, Keller J, LeViere A, Quinlivan EB. Past Care Predicts Future Care in Out-of-Care People Living with HIV: Results of a Clinic-Based Retention-in-Care Intervention in North Carolina. AIDS Behav. 2018 Aug; 22(8):2687-2697.
Score: 0.039
-
O'Connor J, Vjecha MJ, Phillips AN, Angus B, Cooper D, Grinsztejn B, Lopardo G, Das S, Wood R, Wilkin A, Klinker H, Kantipong P, Klingman KL, Jilich D, Herieka E, Denning E, Abubakar I, Gordin F, Lundgren JD. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per µL: secondary outcome results from a randomised controlled trial. Lancet HIV. 2017 03; 4(3):e105-e112.
Score: 0.035
-
Floris-Moore MA, Mollan K, Wilkin AM, Johnson MA, Kashuba AD, Wohl DA, Patterson KB, Francis O, Kronk C, Eron JJ. Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results. Antivir Ther. 2016; 21(1):55-64.
Score: 0.032
-
Molina JM, Podsadecki TJ, Johnson MA, Wilkin A, Domingo P, Myers R, Hairrell JM, Rode RA, King MS, Hanna GJ. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses. 2007 Dec; 23(12):1505-14.
Score: 0.019